Sinubi Tablet 25 mg (Sitagliptin Hydrochloride Monohydrate)

Adult dose

This medication is administered at a dose of 100 mg once daily for monotherapy or combination therapy, with a maximum daily dose of 100 mg. It can be taken regardless of meals. Patients with renal impairment require dosage adjustments based on their kidney function. - Mild renal impairment (eGFR 60 to < 90): No dosage adjustment required - Moderate renal impairment (eGFR 45 to < 60): No dosage adjustment required - Moderate renal impairment (eGFR 30 to < 45): 50 mg once daily - Severe renal impairment (eGFR 15 to < 30) or end-stage renal disease (ESRD) requiring dialysis (eGFR < 15): 25 mg once daily. This medication can be administered regardless of the timing of dialysis.

This medication can rarely cause serious allergic reactions. Such reactions may occur within the first 3 months of taking the medication, so caution is necessary. During the use of this medication, symptoms of acute pancreatitis, which is inflammation of the pancreas, may occur. Therefore, if symptoms such as abdominal pain or vomiting arise, consult a physician immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in individuals who are allergic to this medication or its components. Patients with impaired kidney function may need dosage adjustments, so renal function should be monitored regularly. This medication may cause hypoglycemia, so blood sugar levels should be closely monitored, especially when taken together with other antidiabetic agents like insulin or sulfonylureas. Patients may experience headaches, upper respiratory infections, nasopharyngitis, dyspepsia, diarrhea, and other symptoms during treatment. Report any persistent symptoms to a physician. This medication is not recommended for use in pregnant or nursing women, and its safety and efficacy have not been established in children or adolescents under 18 years of age. When administering to elderly patients, adjust the dosage considering the potential decline in kidney function, and regular kidney function tests are advised. In case of overdose, gastrointestinal decontamination and monitoring of conditions such as ECG may be required, and some removal can occur through hemodialysis. This medication has low interaction potential with other drugs, but caution is advised when used with digoxin or cyclosporine, and consultation with a physician is necessary. If symptoms such as joint pain or skin blisters occur during treatment, inform medical personnel immediately, and discontinue medication when necessary.

Serious side effects

• Urticaria
• angioedema
• anaphylaxis
• Stevens-Johnson syndrome
• exfoliative skin disease
• acute pancreatitis
• acute renal failure
• severe joint pain with disability
• bullous pemphigoid
• pneumonia

Mild side effects

• Upper respiratory infection
• nasopharyngitis
• headache
• diarrhea
• abdominal pain
• nausea
• constipation
• vomiting
• muscle pain
• limb pain

This medication should be stored in a tight container that is not exposed to air, and it is best kept at a temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's efficacy and prevent degradation.

Appearance

Pink, round, biconvex film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]